Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 18 January 2017, 13:23 HKT/SGT
Share:
    

Source: Eisai
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases
Accelerating Access to Health Care in Low and Lower-Middle Income Countries

TOKYO, Jan 18, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it is participating in Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries.

Access Accelerated is the first multi-stakeholder, international initiative in the field of NCDs, consisting of 22 major pharmaceutical companies, including Eisai, in collaboration with the World Bank Group and the Union for International Cancer Control (UICC). The aim of Access Accelerated is to work towards the United Nation's Sustainable Development Goal target of reducing the number of premature deaths from NCDs in low and lower-middle income countries by one-third by 2030. In addition to the individual programs to improve access to health care run by each of the participating companies, this initiative will conduct pilots for improving prevention, treatment and care of NCDs in collaboration with the World Bank Group. Furthermore, in collaboration with the UICC, this initiative will support the provision of effective, sustainable diagnosis and treatment, for the purpose of improving cancer treatment and care.

To address global NCDs issues, Eisai has been running various initiatives in each country to improve access, including an Alzheimer's disease awareness and early detection campaign in China, and the introduction of tiered pricing, an affordable pricing model for our global product anticancer agent Halaven in seven Asian countries, including India, Thailand and the Philippines, where prices are set at several levels in accordance with the income levels of patients.

With regard to Eisai's participation in Access Accelerated, CEO Haruo Naito commented "One of the missions of the modern pharmaceutical industry is to make drugs accessible to all patients, no matter their socioeconomic status. In line with its human health care (hhc) philosophy, Eisai is pleased to take part in
initiatives like Access Accelerated to help address the social and medical needs of patients and their caregivers. For Eisai, pursuing solutions for global access challenges is both our responsibility and a long-term investment into the future."

About Access Accelerated

Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving NCDs care. Involving more than 20 pharmaceutical companies, the initiative works with partners such as World Bank Group and the Union for International Cancer Control (UICC) to help overcome a variety of access barriers to NCDs medicines in low-income and lower-middle income countries. Access Accelerated will support multi-stakeholder dialogue and begin on-the-ground work to improve NCDs prevention, diagnosis and treatment.

Contributing companies include: Almirall, Astellas, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, EFPIA, GlaxoSmithKline, The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Johnson & Johnson, JPMA, Menarini, Merck KGaA, MSD, Novartis, Pfizer, PhRMA, Roche, Sanofi, Shionogi, Sumitomo Dainippon, Takeda and UCB. IFPMA will act as the Secretariat for Access Accelerated.

About Non-Communicable Diseases (NCDs)

NCDs, including cancers, cardiovascular diseases, chronic respiratory disease, diabetes and mental health disorders are the leading causes of death and disability worldwide. An estimated 80% of NCD-related deaths occur in low and lower-middle income countries, and countermeasures for NCDs have become an urgent issue.

About Eisai's initiatives for improving Access to Medicine

Eisai considers its activities for improving access to medicine in developing and emerging countries as a form of long-term investment for future growth, and is currently running various proactive, sustainable initiatives.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Jan 18, 2017 13:23 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 19, 2017 12:21 HKT/SGT
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis
Apr 11, 2017 11:42 HKT/SGT
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series
Apr 5, 2017 10:23 HKT/SGT
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson's Disease Drug Safinamide in Japan and Asia
Apr 5, 2017 10:12 HKT/SGT
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting
Apr 4, 2017 08:56 HKT/SGT
Eisai to Launch Smell Identification Test UPSIT Series in Japan
Mar 29, 2017 10:09 HKT/SGT
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
Mar 29, 2017 09:08 HKT/SGT
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma
Jan 25, 2017 07:59 HKT/SGT
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
Jan 24, 2017 17:43 HKT/SGT
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam
Jan 16, 2017 08:19 HKT/SGT
Transfer of Rights to Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: